(Q30652553)

25 June 2017

1 reference

Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data (English)

1 reference

25 June 2017

1 reference

1 reference

1 reference

1 reference

Koch A

1

1 reference

25 June 2017

Ziegler S

series ordinal

2

1 reference

25 June 2017

Breitschwerdt H

series ordinal

3

1 reference

25 June 2017

Victor N

series ordinal

4

1 reference

25 June 2017

publication date

1 May 2001

1 reference

25 June 2017

1 reference

25 June 2017

volume

102

1 reference

25 June 2017

issue

4

1 reference

25 June 2017

page(s)

295-309

1 reference

Detecting the effects of thromboprophylaxis: the case of the rogue reviews

25 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900251-1

7 January 2021

Meta-analysis of the literature or of individual patient data: is there a difference?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900251-1

7 January 2021

Discrepancies between meta-analyses and subsequent large randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900251-1

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900251-1

7 January 2021

The statistical basis of meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900251-1

7 January 2021

Heparin/dihydroergotamine for venous thrombosis prophylaxis: comparison of low-dose heparin and low molecular weight heparin in hip surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900251-1

7 January 2021

Prevention of thromboembolism in hip-fracture patients. Comparison of low-dose heparin and low-molecular-weight heparin combined with dihydroergotamine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900251-1

7 January 2021

Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900251-1

7 January 2021

Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900251-1

7 January 2021

Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. H.B.P.M. Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900251-1

7 January 2021

Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. A randomized trial. The German Hip Arthroplasty Trial (GHAT) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900251-1

7 January 2021

10.1016/S0049-3848(01)00251-1

Identifiers

DOI

1 reference

25 June 2017

1 reference